Compare Cassava Sciences Inc (FLNA) vs Select Medical Holdings Corporation (SEM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Select Medical Holdings Corporation — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Select Medical Holdings Corporation trades at $16.51 (market cap $2.05B). The key difference: Select Medical Holdings Corporation is far larger — about 38.6× Cassava Sciences Inc's market cap, and Select Medical Holdings Corporation pays a 1.51% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | SEM | |
|---|---|---|
Market Cap | $53.14M | $2.05B |
Sector | Health | Health |
52-Week High | $4.64 | $16.66 |
52-Week Low | $1.09 | $11.77 |
Enterprise Value | -$33.43M | $5.01B |
Dividend Yield | — | 1.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
Select Medical Holdings Corporation (SEM) trades at $16.51, unchanged on the day. The stock's technical outlook is mixed with a bullish overall signal but bearish moving averages. Fundamentally, the company reported 2025 revenue of $5.45 billion and net income of $146.22 million, with a P/E ratio of 15.43. Recent news highlights the completion of its acquisition by a consortium led by Robert A. Ortenzio and Martin F. for $16.50 per share, finalized on June 30, 2026.
The acquisition at $16.50 per share, slightly below the current price, represents a key near-term catalyst but is under legal scrutiny for potential fiduciary breaches. Analyst sentiment is cautious with a 'Hold' consensus. Risks include integration challenges post-acquisition and margin pressures, with net profit margin declining to 2.41% in 2026. The stock offers limited upside from current levels given the acquisition price cap.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Select Medical Holdings Corporation
Select Medical Holdings Corporation is one of the largest operators of critical illness recovery hospitals, rehabilitation hospitals, outpatient rehabilitation clinics, and occupational health centers in the United States. The company's services focus on treating patients with serious illnesses, injuries, and post-acute care needs. SEM provides specialized care across various settings, aiming to help patients recover and return home.
Read more on SEM →
